The incidence of lymph node metastasis in submucosal early gastric cancer according to the expanded criteria: a systematic review
- 180 Downloads
For successful endoscopic treatment of early gastric cancer (EGC), absolute criteria for a curative en bloc resection were initially established to include predominantly differentiated mucosal lesions ≤ 2 cm in diameter without ulceration. These indications were subsequently expanded to include larger, ulcerated, and predominantly undifferentiated mucosal lesions. In addition, differentiated type adenocarcinomas ≤ 3 cm with slight submucosal invasion of < 500 µm (pT1b1) are regarded as “curative” under the expanded criteria. However, data derived from studies of surgical specimens in patients with pT1b1 EGC have yielded varying rates of lymph node metastasis (LNM).
A systemic review was conducted using the pooled analysis to calculate the incidence of LNM in pT1b1 EGC, and to investigate whether using a cut-off value of < 300 µm would decrease the risk of LNM in patients with submucosal EGC.
Nineteen articles were included. 1507 patients with pT1b1 EGC met the expanded indications. The incidence of LNM was 3% (45 out of 1507 patients). In a subgroup analysis of three studies, there was no significant difference in the LNM between pT1b EGC < 300 µm and < 500 µm [3/121(2.5%) vs. 5/180 (2.8%)] (OR 0.89, 95% CI 0.22–3.54).
Overall, expanding the indications for endoscopic resection of EGC to include lesions ≤ 3 cm T1b1 is associated with a potential risk of LNM of 3%. In countries outside of Japan, we found a slightly higher risk of LNM (4.0%). These estimates of LNM should be incorporated into decisions regarding further management of patients with EGC ≤ 3 cm who are found to have slight submucosal invasion (< 500 µm) in an ESD specimen. Standardization of specimen handling and histological evaluation is essential if the Japanese results of endoscopic treatment for EGC are to be successfully applied in other parts of the world.
KeywordsForegut Esophagus and stomach Surgery/interventions Malignant gastric diseases
Compliance with ethical standards
Dr. Ian S. Grimm is a consultant at Boston Scientific. Mohamed M. Abdelfatah, Mohamed Barakat, Mohamed O. Othman, and Noriya Uedo declare that they have no conflict of interest or financial ties to disclose.
- 3.Hiki Y (1996) Endoscopic mucosal resection (EMR) for early gastric cancer. Nihon Geka Gakkai Zasshi 97:273–278Google Scholar
- 15.Omote K, Mai M, Mizoguchi M, Takahashi Y, Kawashima A (1997) Degree of submucosal invasion of early gastric carcinoma and risk for lymph node metastasis: consideration limiting of applicability for endoscopic resection. Stomach Intest 32:49–55 (in Japanese, with abstract in English)Google Scholar
- 36.Abdelfatah MM, Barakat M, Lee H et al (2017) The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. Gastrointest Endosc 87:338–347CrossRefGoogle Scholar
- 41.(1991) Advances in experimental medicine and biology. Plasticity and regeneration of the nervous system. Adv Exp Med Biol 296:1–352Google Scholar
- 46.Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev 2015:CD009944Google Scholar
- 48.Tajiri H, Ohtsu A, Boku N et al (2001) Routine endoscopy using electronic endoscopes for gastric cancer diagnosis: retrospective study of inconsistencies between endoscopic and biopsy diagnoses. Cancer Detect Prev 25:166–173Google Scholar